ImmunoMet Announces Initiation of Phase 1 Clinical Study of IM156, an OXPHOS Inhibitor, in Patients with Solid Tumors > Investors & Media

본문 바로가기


Investors & Media


Copyright © ImmunoMet. All rights reserved.